Interview with John Dawson, Founder & CEO, Alliance Pharma plc
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we…
Address: Avonbridge House, Bath Road, Chippenham, Wiltshire SN15 2BB, United Kingdom ,United Kingdom
Tel: +44 (0)1249 466966
Web: http://www.camb-labs.com/default.asp
Alliance is a speciality pharmaceutical group based in the United Kingdom and listed on AIM. The group was founded in 1998 and since then has established a strong track record of acquiring the rights to established niche products. Alliance now owns or licences over 50 prescription products. Pro forma annual sales now exceed £40m.
Alliance maintains strategic and controlling functions with a management team possessing considerable large pharmaceutical company experience. More labour and capital intensive functions are outsourced to maximise efficiency and profitability.
The core of Alliances’ activities are in the United Kingdom and the Republic of Ireland. The group also sells into approximately 20 other countries Worldwide, including via a joint venture into China.
Anti Infective, Cough, Cold & Flu
Cardiovascular
Central Nervous System
Dental
Dermatology
Diagnostics
Nutrition
Obstetrics & Gynaecology
Rheumatology
Toxicology
Oncology
Endocrinology
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we…
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
After a series of recent acquisitions, developing a diverse portfolio comprising four business areas; including OTC and branded prescription medicines, Mylan UK’s country manager, Jean-Yves Brault, takes a step back…
Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance…
With an appetite to take the next step in its rapid development, EUSA Pharma has already established itself as a leading rare-disease and oncology biotech company in just a short…
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and…
Liam O’Toole, CEO of Arthritis Research UK, discusses how arthritis impacts the British economy, raising public awareness of the condition, the potential ramifications of Brexit, and the importance of inter-stakeholder…
Mark Hicken, managing director of the UK and Ireland operations of Janssen, the pharmaceutical arm of Johnson & Johnson, highlights the company’s long-standing R&D presence in the UK. He calls…
Sir Robert Lechler, president of the Academy of Medical Sciences (AMS), discusses the Academy’s role in promoting medical research in the UK and how that stands to change in the…
Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international…
Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with…
Sir John Savill, chief executive of the Medical Research Council between 2010 and 2018, discusses the organization’s transition into part of the new UK Research and Innovation (UKRI) grouping, the…
Steve Ford, CEO of Parkinson’s UK, one of the UK’s leading research-based charities, discusses his organization’s recent Digital Leadership Award, presenting the needs of Parkinson’s patients to stakeholders, and why…
See our Cookie Privacy Policy Here
